This article was written by Jonathan Andrus, Chief Strategy Officer at Clinical Ink to appear in the August 2019 Expert Opinion issue of Contract Pharma.
In this article you’ll learn:
- How EDC methods and technologies empower more successful RBM strategies
- What to consider when planning and conducting RBM for trials
- What tools and technologies are available that can help organizations embrace a comprehensive risk-based approach